{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T05:46:13Z","timestamp":1769751973143,"version":"3.49.0"},"reference-count":79,"publisher":"Begell House","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Immunol"],"published-print":{"date-parts":[[2022]]},"abstract":"<p>Immune system escape is one of the major strategies required for cancer growths. In this scenario, the advent of immune checkpoint inhibitors (ICIs) revolutionized the landscape of treatment options for tumors. Despite their wide use, these agents are associated with a unique spectrum of toxicities known as immune-related adverse events (irAEs). IrAEs are cause of treatment suspension (up to 60&amp;#37; of all causes of treatment interruption) and potentially impact on patients' quality of life. These toxicities are the main limitations on the use of these innovative drugs. IrAEs are peculiar, due to the mechanism of actions of ICIs, and any body organs may be involved (skin, thyroid, colon, lungs, in particular). Thus, the management often requires a multidisciplinary approach. The aim of this manuscript is to review current literature on autoimmune skin diseases described in association with ICIs (i.e., vitiligo, lupus erythematosus, vasculitis, morphea\/scleroderma, alopecia areata, bullous pemphigoid, dermatomyositis), in order to provide a comprehensive overview for the physician.<\/p>","DOI":"10.1615\/critrevimmunol.2023047032","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T19:19:51Z","timestamp":1672946391000},"page":"11-22","source":"Crossref","is-referenced-by-count":5,"title":["Autoimmune Skin Diseases and Immune Checkpoint Inhibitors"],"prefix":"10.1615","volume":"42","author":[{"given":"Davide","family":"Fattore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Genco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile","family":"Pages","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariadna","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"613","reference":[{"issue":"7637","key":"1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen D.S.","year":"2017","journal-title":"Nature"},{"key":"2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jprot.2017.08.010","article-title":"Clinical multiomics strategies for the effective cancer management","volume":"188","author":"Yoo B.C.","year":"2018","journal-title":"J Proteomics"},{"key":"3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint in-hibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi S.","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"4","unstructured":"Yervoy. Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yervoy-epar-product-information_en.pdf [Cited 2022 Oct 15]."},{"key":"5","unstructured":"Opdivo. Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/opdivo-epar-product-information_en.pdf [Cited 2022 Oct 15]."},{"key":"6","unstructured":"Keytruda. Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf [Cited 2022 Oct 15]."},{"key":"7","unstructured":"Imfinzi. Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imfinzi-epar-product-information_en.pdf [Cited 2022 Oct 15]."},{"key":"8","unstructured":"Bavencio. Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bavencio-epar-product-information_en.pdf [Cited 2022 Oct 15]."},{"key":"9","unstructured":"Tecentriq. Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecentriq-epar-product-information_en.pdf [Cited 2022 Oct 15]."},{"key":"10","unstructured":"Libtayo. Summary of product characteristics. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product- information\/libtayo-epar-product-information_en.pdf [Cited 2022 Oct 15]."},{"issue":"5","key":"11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler A.N.","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy","volume":"19","author":"Sibaud V.","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/14740338.2022.1993819","article-title":"Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma","volume":"21","author":"Villani A.","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126388","article-title":"The treatment of advanced melanoma: Therapeutic update","volume":"23","author":"Villani A.","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"12","key":"15","article-title":"Adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow M.A.","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2021.06.040","article-title":"Immune checkpoint blockade and skin toxicity pathogenesis","volume":"142","author":"Ma B.","year":"2022","journal-title":"J Invest Dermatol"},{"key":"17","article-title":"Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective study","author":"Freites-Martinez A.","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/CMR.0000000000000819","article-title":"Severe blistering eruptions induced by immune checkpoint inhibitors: A multicentre international study of 32 cases","volume":"32","author":"Ingen-Housz-Oro S.","year":"2022","journal-title":"Melanoma Res"},{"issue":"3","key":"19","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.17855","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement","volume":"36","author":"Apalla Z.","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: A review","volume":"236","author":"Bergqvist C.","year":"2020","journal-title":"Dermatology"},{"key":"21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: Mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli M.L.","year":"2020","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua C.","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"5","key":"23","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jaad.2017.06.044","article-title":"Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis","volume":"77","author":"Dai J.","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"24","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100064","article-title":"Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: An Italian Melanoma Intergroup study","volume":"6","author":"Guida M.","year":"2021","journal-title":"ESMO Open"},{"issue":"3","key":"25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2018.04.046","article-title":"Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy","volume":"79","author":"Rzepecki A.K.","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study","volume":"44","author":"Nakamura Y.","year":"2017","journal-title":"J Dermatol"},{"issue":"2","key":"27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2016.10.008","article-title":"Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding","volume":"3","author":"Yin E.S.","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"2","key":"28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura H.","year":"1999","journal-title":"Immunity"},{"issue":"3","key":"29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/CMR.0000000000000587","article-title":"Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: A report of three cases","volume":"29","author":"Blakeway E.A.","year":"2019","journal-title":"Melanoma Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejca.2020.12.017","article-title":"Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy","volume":"145","author":"Andersson N.W.","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ced.14449","article-title":"De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: Clinicopathological correlation","volume":"46","author":"Bui A.N.","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"32","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/bjd.17245","article-title":"Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy","volume":"181","author":"Marano A.L.","year":"2019","journal-title":"Br J Dermatol"},{"issue":"9","key":"33","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner B.M.","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"34","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1634\/theoncologist.2019-0467","article-title":"Sicca syndrome induced by immune checkpoint inhibitor therapy: Optimal management still pending","volume":"25","author":"Ortiz Brugues A.","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine M.","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"36","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini A.","year":"2018","journal-title":"Clin Rheumatol"},{"key":"37","article-title":"A rare case of large-vessel vasculitis following checkpoint inhibitor therapy and pegfilgrastim","volume":"2022","author":"Mort J.","year":"2022","journal-title":"Case Rep Oncol Med"},{"issue":"3","key":"38","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/annrheumdis-2016-210820","article-title":"Onset of connective tissue disease following anti-PD1\/PD-L1 cancer immunotherapy","volume":"77","author":"Le Burel S.","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/dtb.2020.233496rep","article-title":"Republished: Immune checkpoint inhibitor induced large vessel vasculitis","volume":"59","author":"Henderson D.","year":"2021","journal-title":"Drug Ther Bull"},{"issue":"1","key":"40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5152\/eurjrheum.2019.19061","article-title":"Isolated testicular vasculitis due to immune checkpoint inhibitor","volume":"7","author":"Weiner R.","year":"2019","journal-title":"Eur J Rheumatol"},{"issue":"1","key":"41","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3313-6","article-title":"Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade","volume":"17","author":"Gambichler T.","year":"2017","journal-title":"BMC Cancer"},{"key":"42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejim.2018.07.023","article-title":"Anti-PDl therapy-associated cutaneous leucocytoclastic vasculitis: A case series","volume":"57","author":"Tomelleri A.","year":"2018","journal-title":"Eur J Intern Med"},{"key":"43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.803706","article-title":"Frequency of immune checkpoint inhibitor-induced vasculitides: An observational study using data from the japanese adverse drug event report database","volume":"13","author":"Kato K.","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"44","article-title":"Dermatomyositis flare with immune checkpoint inhibitor therapy for melanoma","volume":"13","author":"Thomas R.","year":"2021","journal-title":"Cureus"},{"issue":"19","key":"45","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1111\/1759-7714.14609","article-title":"Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-y antibody-positive dermatomyositis: A case report","volume":"13","author":"Kim Y.","year":"2022","journal-title":"Thorac Cancer"},{"issue":"3","key":"46","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CMR.0000000000000642","article-title":"Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: A case report and review of the literature","volume":"30","author":"Kosche C.","year":"2020","journal-title":"Melanoma Res"},{"issue":"2","key":"47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: A novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali S.","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"1","key":"48","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/08998280.2020.1811189","article-title":"Dermatomyositis, pembrolizumab, and squamous cell carcinoma of the lung","volume":"34","author":"Wiggins C.J.","year":"2021","journal-title":"Baylor University Medical Center Proceedings"},{"issue":"11","key":"49","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/1346-8138.14993","article-title":"Case of dermatomyositis during treatment with pembrolizumab for lung cancer","volume":"46","author":"Hinogami H.","year":"2019","journal-title":"J Dermatol"},{"issue":"9","key":"50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/1346-8138.16426","article-title":"Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-y antibody","volume":"49","author":"Mizumaki K.","year":"2022","journal-title":"J Dermatol"},{"issue":"6","key":"51","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2217\/imt-2020-0309","article-title":"A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis","volume":"13","author":"Kartolo A.","year":"2021","journal-title":"Immunotherapy"},{"issue":"11","key":"52","doi-asserted-by":"crossref","first-page":"768","DOI":"10.5692\/clinicalneurol.cn-001443","article-title":"Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report","volume":"60","author":"Miyashita K.","year":"2020","journal-title":"Rinsho Shinkeigaku"},{"issue":"8","key":"53","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.5070\/D3268049887","article-title":"Dermatomyositis associated with nivolumab therapy for melanoma: A case report and review of the literature","volume":"26","author":"Messer A.","year":"2020","journal-title":"Dermatol Online J"},{"key":"54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2021.06.031","article-title":"Rare cutaneous toxicity of immune checkpoint inhibitors: A case of durvalumab-induced dermatomyositis","volume":"155","author":"Coustal C.","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"55","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jaad.2020.10.054","article-title":"De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysis","volume":"84","author":"Bui A.N.","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"56","doi-asserted-by":"crossref","first-page":"93","DOI":"10.25259\/IJDVL_1306_20","article-title":"Immunotherapy-intensified paraneoplastic dermatomyositis","volume":"88","author":"Estenaga A.","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"18","key":"57","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.2169\/internalmedicine.6917-20","article-title":"Atezolizumab-associated dermatomyositis in advanced small-cell lung carcinoma","volume":"60","author":"Yamaguchi Y.","year":"2021","journal-title":"Intern Med"},{"issue":"15","key":"58","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019741","article-title":"A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors","volume":"99","author":"Ohira J.","year":"2020","journal-title":"Medicine"},{"issue":"1","key":"59","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-019-2105-9","article-title":"Paraneo-plastic dermatomyositis appearing after nivolumab therapy for gastric cancer: A case report","volume":"13","author":"Shibata C.","year":"2019","journal-title":"J Med Case Rep"},{"key":"60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejca.2018.08.021","article-title":"Pembrolizumab-induced dermatomy- ositis in a patient with metastatic melanoma","volume":"104","author":"Berger M.","year":"2018","journal-title":"Eur J Cancer"},{"key":"61","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.930286","article-title":"A rare case of pembrolizumab-induced dermatomyositis in a patient with cancer of unknown primary origin","volume":"22","author":"Takatsuki K.","year":"2021","journal-title":"Am J Case Rep"},{"key":"62","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2019.05.018","article-title":"Generalised morphea induced by pembrolizumab","volume":"116","author":"Herrscher H.","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"63","first-page":"208","article-title":"Scleroderma with an update about clinico-pathological correlation","volume":"153","author":"Rongioletti F.","year":"2018","journal-title":"G Ital Dermatol Venereol"},{"issue":"2","key":"64","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000525887","article-title":"Scleroderma-like syndrome in the setting of pembrolizumab therapy for non-small-cell lung cancer: Diagnosis and dermatologic management","volume":"14","author":"Fattore D.","year":"2022","journal-title":"Case Rep Dermatol"},{"issue":"3","key":"65","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2021.06.040","article-title":"Immune checkpoint blockade and skin toxicity pathogenesis","volume":"142","author":"Ma B.","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"3","key":"66","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaad.2018.04.046","article-title":"Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy","volume":"79","author":"Rzepecki A.K.","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"67","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/jdv.17253","article-title":"Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1\/PD-L1 therapy: A national retrospective study","volume":"35","author":"Juzot C.","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"68","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.19313","article-title":"Diagnostic and therapeutic differences between immune checkpoint inhibitor-induced and idiopathic bullous pemphigoid: A cross-sectional study","volume":"183","author":"Molina G.E.","year":"2020","journal-title":"Br J Dermatol"},{"key":"69","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ejca.2018.08.022","article-title":"Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy","volume":"103","author":"Panariello L.","year":"2018","journal-title":"Eur J Cancer"},{"issue":"4","key":"70","first-page":"854","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in Non-small-cell lung cancer patients treated with check-point inhibitors","volume":"82","author":"Hasan Ali O.","year":"2020","journal-title":"JAmAcad Dermatol"},{"issue":"9","key":"71","doi-asserted-by":"publisher","DOI":"10.5070\/D327955136","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: A case report and review of the literature","volume":"27","author":"Klepper E.M.","year":"2021","journal-title":"Dermatol Online J"},{"key":"72","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2019.08.030","article-title":"Pages-Laurent C. Nivolumab-related mucous membrane pemphigoid","volume":"121","author":"Sibaud V.","year":"2019","journal-title":"Eur J Cancer"},{"issue":"3","key":"73","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5021\/ad.2021.33.3.284","article-title":"Nivolumab-induced alopecia areata: A case report and literature review","volume":"33","author":"Kim K.H.","year":"2021","journal-title":"Ann Dermatol"},{"issue":"8","key":"74","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jdcr.2018.05.022","article-title":"Nivolumab-induced alopecia areata: A reversible factor of good prognosis?","volume":"4","author":"Lakhmiri M.","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"6","key":"75","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14171","article-title":"Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: A review","volume":"33","author":"Antoury L.","year":"2020","journal-title":"Dermatol Ther"},{"issue":"6","key":"76","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjd.15237","article-title":"Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors","volume":"176","author":"Zarbo A.","year":"2017","journal-title":"Br J Dermatol"},{"issue":"18","key":"77","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King B.","year":"2022","journal-title":"N Engl J Med"},{"key":"78","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2019.01.012","article-title":"Prurigo nodularis and pembrolizumab: A therapeutic challenge","volume":"110","author":"Fattore D.","year":"2019","journal-title":"Eur J Cancer"},{"key":"79","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.01.010","article-title":"Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast","volume":"110","author":"Fattore D.","year":"2019","journal-title":"Eur J Cancer"}],"container-title":["Critical Reviews in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/5f2a1ac260c0bc14\/CRI-47032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T03:25:14Z","timestamp":1701660314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/2ff21abf44b19838,1b1446c37d2144ce,5f2a1ac260c0bc14.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1615\/critrevimmunol.2023047032","relation":{},"ISSN":["1040-8401"],"issn-type":[{"value":"1040-8401","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}